Mercaptopurine Aspen Pharma Trading Limited

Mercaptopurine, the active ingredient in Mercaptopurine Aspen Pharma Trading Limited, is an antimetabolite presented as an oral formulation for oral use. It is employed in the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, and certain inflammatory bowel diseases, targeting malignant and proliferating cells.

GNH USA supplies Mercaptopurine Aspen Pharma Trading Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical and commercial use.

Mercaptopurine is an antimetabolite used in hematologic malignancies and inflammatory bowel disease. - Acute lymphoblastic leukemia: helps achieve remission by inhibiting leukemic cell proliferation. - Acute myeloid leukemia: contributes to disease control through suppression of malignant myeloid cells. - Inflammatory bowel disease: reduces intestinal inflammation by limiting immune cell turnover.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Bone marrow suppression (e.g., neutropenia) - Fatigue - Elevated liver enzymes

Serious or Rare Side Effects: - Severe myelosuppression leading to infection or bleeding - Hepatotoxicity with jaundice or liver failure - Pancreatitis - Secondary malignancies - Severe hypersensitivity reactions

Precautions are essential to minimize toxicity and monitor patient safety. - Monitor blood counts: regular CBC testing to detect myelosuppression. - Assess liver function: periodic LFTs due to risk of hepatotoxicity. - Evaluate renal function: dose adjustments may be needed in renal impairment. - Avoid use in pregnancy unless essential: category D, potential fetal risk. - Counsel on infection risk: advise patients to report fever or signs of infection promptly. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Mercaptopurine interacts with several drugs that may alter its safety or efficacy. Major Interactions (Avoid): - Allopurinol: may increase mercaptopurine toxicity; dose reduction required. - TPMT deficiency: high risk of severe myelosuppression. - Azathioprine: additive immunosuppression, increased bone marrow suppression. Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Oral contraceptives: reduced efficacy, consider alternative contraception.